Regulations.gov document
Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were…
Notice · FDA-2022-P-0558 · posted Sep 13, 2023
Key facts
| Document ID | FDA-2022-P-0558-0003 |
|---|---|
| Title | Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2022-P-0558 |
| Posted | Sep 13, 2023 |
| Federal Register citation | 88 FR 62799 |
| FR document number | 2023-19796 |
| Effective date | Sep 13, 2023 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: